Glycosaminoglycans as Novel Targets for in vivo Contrast-Enhanced Magnetic Resonance Imaging of Atherosclerosis
Article Sidebar
Main Article Content
Abstract
Atherosclerosis is an important promoter of cardiovascular disease potentiating myocardial infarction or stroke. Current demand in biomedical imaging necessitates noninvasive characterization of arterial changes responsible for transition of stable plaque into rupture-prone vulnerable plaque. in vivo contrast enhanced magnetic resonance (MR) imaging (MRI) allows quantitative and functional monitoring of pathomorphological changes through signal differences induced by the contrast agent uptake in the diseased vessel wall, therefore it is the ideal modality toward this goal. However, studies have so far focused on the cellular targets of persisting inflammation, leaving extracellular matrix (ECM) far behind. In this review, we portray ECM remodeling during atherosclerotic plaque progression by summarizing the state of the-art in MRI and current imaging targets. Finally, we aim to discuss glycosaminoglycans (GAGs) and their functional interactions, which might offer potential toward development of novel imaging probes for in vivo contrast-enhanced MRI of atherosclerosis.
Article Details
Copyright (c) 2020 Uca YO, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ross R. Atherosclerosis — An Inflammatory Disease. N Engl J Med. 1999; 340: 115–126. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9887164 DOI: https://doi.org/10.1056/NEJM199901143400207
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2019 update: a report From the American Heart Association. Circulation. 2019; 139 :526–528. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30700139
Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014; 35: 2950–2959. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25139896 DOI: https://doi.org/10.1093/eurheartj/ehu299
Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association. Circulation. 2011; 123: 933–944. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21262990 DOI: https://doi.org/10.1161/CIR.0b013e31820a55f5
Nojiri S, Daida H. Atherosclerotic Cardiovascular Risk in Japan. Jpn Clin Med [Internet]. 2017; 8. PubMed: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480958/ DOI: https://doi.org/10.1177/1179066017712713
Pozo E, Agudo-Quilez P, Rojas-González A, Alvarado T, Olivera MJ, et al. Noninvasive diagnosis of vulnerable coronary plaque. World J Cardiol. 2016; 8: 520–533. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039354/ DOI: https://doi.org/10.4330/wjc.v8.i9.520
Tarkin JM, Dweck MR, Evans NR, Takx RA, Brown AJ, et al. Imaging atherosclerosis. Circ Res. 2016; 118: 750–769. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26892971 DOI: https://doi.org/10.1161/CIRCRESAHA.115.306247
Skinner MP, Yuan C, Mitsumori L, Hayes CE, M.p.s EWR, Nelson JA, et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med. 1995; 1: 69–73. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7584956 DOI: https://doi.org/10.1038/nm0195-69
Toussaint J-F, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic Resonance Images Lipid, Fibrous, Calcified, Hemorrhagic, and Thrombotic Components of Human Atherosclerosis in vivo. Circulation. 1996; 94: 932–8. DOI: https://doi.org/10.1161/01.CIR.94.5.932
Botnar RM, Stuber M, Kissinger KV, Kim WY, Spuentrup E, et al. Noninvasive Coronary Vessel Wall and Plaque Imaging With Magnetic Resonance Imaging. Circulation. 2000; 102: 2582–2587. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11085960 DOI: https://doi.org/10.1161/01.CIR.102.21.2582
Fayad ZA, Fuster V. Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque. Circ Res. 2001; 89: 305–316. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11509446 DOI: https://doi.org/10.1161/hh1601.095596
Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, et al. Iron Oxide Particles for Atheroma Imaging. Arterioscler Thromb Vasc Biol. 2009; 29:1001–1008. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19229073 DOI: https://doi.org/10.1161/ATVBAHA.108.165514
Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation. 1995; 92: 657–671. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7634481 DOI: https://doi.org/10.1161/01.CIR.92.3.657
Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, N T, et al. Atherosclerotic Plaque Progression and Vulnerability to Rupture.
Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med. 2005; 352: 1685–1695. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15843671 DOI: https://doi.org/10.1056/NEJMra043430
Libby P, DiCarli M, Weissleder R. The Vascular Biology of Atherosclerosis and Imaging Targets. J Nucl Med. 2010; 51(Supplement 1): 335-375. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20395349 DOI: https://doi.org/10.2967/jnumed.109.069633
Rudd JHF, Hyafil F, Fayad ZA. Inflammation Imaging in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2009; 29: 1009–1016. DOI: https://doi.org/10.1161/ATVBAHA.108.165563
Reimann C, Brangsch J, Colletini F, Walter T, Hamm B, Botnar RM, et al. Molecular imaging of the extracellular matrix in the context of atherosclerosis. Adv Drug Deliv Rev. 2017; 113:49–60. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27639968 DOI: https://doi.org/10.1016/j.addr.2016.09.005
Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the Vulnerable Plaque. J Am Coll Cardiol. 2006; 47(8 Supplement): C13–18. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16631505 DOI: https://doi.org/10.1016/j.jacc.2005.10.065
Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy. Pharmacol Rev. 2009; 61:198–223. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830117/s DOI: https://doi.org/10.1124/pr.109.001289
Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 2005; 23: 47–55. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15637621 DOI: https://doi.org/10.1038/nbt1055
Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21: 1104–1108. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16431890 DOI: https://doi.org/10.1093/ndt/gfk062
George S j., Webb S m., Abraham J l., Cramer S p. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol. 2010; 163: 1077–1081. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20560953 DOI: https://doi.org/10.1111/j.1365-2133.2010.09918.x
Laurent S, Vander Elst L, Henoumont C, Muller RN. How to measure the transmetallation of a gadolinium complex. Contrast Media Mol Imaging. 2010; 5: 305–308. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20803503 DOI: https://doi.org/10.1002/cmmi.388
Taupitz M, Stolzenburg N, Ebert M, Schnorr J, Hauptmann R, Kratz H, et al. Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd 3+ to the glycosaminoglycan heparin: GdCM, Glycosaminoglycans and Transchelation. Contrast Media Mol Imaging. 2013; 8:108–116. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23281283 DOI: https://doi.org/10.1002/cmmi.1500
Narula J, Virmani R, Iskandrian AE. Strategic targeting of atherosclerotic lesions. J Nucl Cardiol. 1999; 6: 81–90. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10070844 DOI: https://doi.org/10.1016/S1071-3581(99)90068-5
Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, et al. Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling: Molecular, Cellular, and Vascular Behavior. J Am Coll Cardiol. 2007; 49: 2379–2393. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17599600 DOI: https://doi.org/10.1016/j.jacc.2007.02.059
Gimbrone MA, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesisa. Ann N Y Acad Sci. 2000; 902: 230–240. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10865843 DOI: https://doi.org/10.1111/j.1749-6632.2000.tb06318.x
Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. The Pathogenesis of Atherosclerosis-The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004; 45: 993–1007. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15060092 DOI: https://doi.org/10.1194/jlr.R400001-JLR200
Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170: 191–203. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14612198 DOI: https://doi.org/10.1016/S0021-9150(03)00097-2
Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With αvβ3-Integrin–Targeted Nanoparticles. Circulation. 2003; 108: 2270–2274. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14557370 DOI: https://doi.org/10.1161/01.CIR.0000093185.16083.95
Galkina E, Ley K. Vascular Adhesion Molecules in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27: 2292–2301. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17673705 DOI: https://doi.org/10.1161/ATVBAHA.107.149179
Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, et al. Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle. Circ Res. 2005; 96: 327–336. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15653572 DOI: https://doi.org/10.1161/01.RES.0000155722.17881.dd
Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, et al. Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis. Circulation. 2006; 114: 1504–1511. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17000904 DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.646380
Briley-Saebo KC, Shaw PX, Mulder WJM, Choi S-H, Vucic E, et al. Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. Circulation. 2008; 117: 3206–3215. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18541740 DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.757120
McAteer MA, Schneider JE, Ali ZA, Warrick 1 Nicholas, Bursill CA, et al. Magnetic Resonance Imaging of Endothelial Adhesion Molecules in Mouse Atherosclerosis Using Dual-Targeted Microparticles of Iron Oxide. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):77–83. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17962629 DOI: https://doi.org/10.1161/ATVBAHA.107.145466
Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest. 1998; 101: 1551–1556. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9541483 DOI: https://doi.org/10.1172/JCI1568
Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874. DOI: https://doi.org/10.1038/nature01323
Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JGS, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci. 2007; 104: 961–966. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17215360 DOI: https://doi.org/10.1073/pnas.0606281104
Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits. Circulation. 2001; 103: 415–422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11157694 DOI: https://doi.org/10.1161/01.CIR.103.3.415
Schmitz SA, Taupitz M, Wagner S, Wolf K-J, Beyersdorff D, et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001; 14: 355–361. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11599058 DOI: https://doi.org/10.1002/jmri.1194
Kooi ME, Cappendijk VC, Cleutjens KBJM, Kessels AGH, Kitslaar PJEHM, et al. Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by in vivo Magnetic Resonance Imaging. Circulation. 2003; 107: 2453–2458. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12719280 DOI: https://doi.org/10.1161/01.CIR.0000068315.98705.CC
Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, et al. in vivo Imaging of Proteolytic Activity in Atherosclerosis. Circulation. 2002; 105: 2766–2771. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12057992 DOI: https://doi.org/10.1161/01.CIR.0000017860.20619.23
Deguchi J, Aikawa M, Tung C-H, Aikawa E, Kim D-E, et al. Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages in vivo. Circulation. 2006 Jul 4;114(1):55–62. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16801460 DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.619056
Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci. 1996; 93: 3942–3946. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC39464/ DOI: https://doi.org/10.1073/pnas.93.9.3942
Hyafil F, Vucic E, Cornily J-C, Sharma R, Amirbekian V, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J. 2011; 32: 1561–1571. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21118852 DOI: https://doi.org/10.1093/eurheartj/ehq413
Helske S, Syväranta S, Lindstedt KA, Lappalainen J, Öörni K, et al. Increased Expression of Elastolytic Cathepsins S, K, and V and Their Inhibitor Cystatin C in Stenotic Aortic Valves. Arterioscler Thromb Vasc Biol. 2006; 26: 1791–1798. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16728655
Majmudar MD, Nahrendorf M. Cardiovascular Molecular Imaging: The Road Ahead. J Nucl Med. 2012; 53: 673–676. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22492729 DOI: https://doi.org/10.2967/jnumed.111.099838
Lairez O, Fayad ZA. Imaging of atherosclerosis: Can molecular imaging do more? Arch Cardiovasc Dis. 2013; 106: 551–553. DOI: https://doi.org/10.1016/j.acvd.2013.06.001
Carlier S, Kakadiaris IA, Dib N, Vavuranakis M, O’Malley SM, et al. Vasa vasorum imaging: A new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Atheroscler Rep. 2005; 7: 164–169. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15727733 DOI: https://doi.org/10.1007/s11883-005-0040-2
Vakonakis I, Campbell ID. Extracellular matrix: from atomic resolution to ultrastructure. Curr Opin Cell Biol. 2007; 19: 578–583. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17942296 DOI: https://doi.org/10.1016/j.ceb.2007.09.005
Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med. 1998; 76: 253–265. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9535559 DOI: https://doi.org/10.1007/s001090050215
Katsuda S, Kaji T. Atherosclerosis and Extracellular Matrix. J Atheroscler Thromb. 2003; 10: 267–274. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14718743 DOI: https://doi.org/10.5551/jat.10.267
Wight TN, Lara S, Riessen R, Le Baron R, Isner J. Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. Am J Pathol. 1997; 151: 963-973. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9327730
Wight TN, Merrilees MJ. Proteoglycans in Atherosclerosis and Restenosis: Key Roles for Versican. Circ Res. 2004; 94: 1158–1167. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15142969 DOI: https://doi.org/10.1161/01.RES.0000126921.29919.51
Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, et al. Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin. Circ Res. 2004; 95: 1225–1233. DOI: https://doi.org/10.1161/01.RES.0000150373.15149.ff
Ye F, Jeong E-K, Jia Z, Yang T, Parker D, et al. A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI. Bioconjug Chem. 2008; 19: 2300–2303. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19053180 DOI: https://doi.org/10.1021/bc800211r
Mayne R. Collagenous proteins of blood vessels. Arterioscler Thromb Vasc Biol. 1986; 6: 585–593. DOI: https://doi.org/10.1161/01.ATV.6.6.585
Brodsky B, Persikov AV. Molecular Structure of the Collagen Triple Helix. Adv Protein Chem. 2005; 70: 301–339. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15837519 DOI: https://doi.org/10.1016/S0065-3233(05)70009-7
Caravan P, Das B, Dumas S, Epstein FH, Helm PA, et al. Collagen-Targeted MRI Contrast Agent for Molecular Imaging of Fibrosis. Angew Chem. 2007; 119: 8319–8321. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17893943 DOI: https://doi.org/10.1002/ange.200700700
Helm PA, Caravan P, French BA, Jacques V, Shen L, Xu Y, et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology. 2008; 247: 788–796. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410958/ DOI: https://doi.org/10.1148/radiol.2473070975
Jimi S, Sakata N, Matunaga A, Takebayashi S. Low density lipoproteins bind more to type I and III collagens by negative charge-dependent mechanisms than to type IV and V collagens. Atherosclerosis. 1994; 107: 109–116. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7945553 DOI: https://doi.org/10.1016/0021-9150(94)90146-5
Khalil MF. Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 2211–2218. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15472124 DOI: https://doi.org/10.1161/01.ATV.0000147163.54024.70
Adiguzel E, Ahmad PJ, Franco C, Bendeck MP. Collagens in the progression and complications of atherosclerosis. Vasc Med. 2009; 14: 73–89. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19144782 DOI: https://doi.org/10.1177/1358863X08094801
Chen W, Cormode DP, Vengrenyuk Y, Herranz B, Feig JE, et al. Collagen-Specific Peptide Conjugated HDL Nanoparticles as MRI Contrast Agent to Evaluate Compositional Changes in Atherosclerotic Plaque Regression. JACC Cardiovasc Imaging. 2013; 6: 373–384. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23433925 DOI: https://doi.org/10.1016/j.jcmg.2012.06.016
Spuentrup E, Ruhl KM, Botnar RM, Wiethoff AJ, Buhl A, et al. Molecular Magnetic Resonance Imaging of Myocardial Perfusion With EP-3600, a Collagen-Specific Contrast Agent: Initial Feasibility Study in a Swine Model. Circulation. 2009; 119: 1768–1775. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19307474 DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.826388
Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, et al. Elastin is an essential determinant of arterial morphogenesis. Nature. 1998; 393: 276–280. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9607766 DOI: https://doi.org/10.1038/30522
Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development. 2003; 130: 411–423. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12466207 DOI: https://doi.org/10.1242/dev.00223
Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS. Contribution of Macromolecular Structure to the Retention of Low-Density Lipoprotein at Arterial Branch Points. Circulation. 2008; 117: 2919–2927. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18506002 DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.754614
Robert L, Robert AM, Jacotot B. Elastin–elastase–atherosclerosis revisited. Atherosclerosis. 1998; 140: 281–295. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9862271 DOI: https://doi.org/10.1016/S0021-9150(98)00171-3
Krettek A, Sukhova GK, Libby P. Elastogenesis in Human Arterial Disease: A Role for Macrophages in Disordered Elastin Synthesis. Arterioscler Thromb Vasc Biol. 2003; 23: 582–587. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12615674 DOI: https://doi.org/10.1161/01.ATV.0000064372.78561.A5
Choudhury Robin P, Valentin F, Badimon Juan J, Fisher Edward A, Fayad Zahi A. MRI and Characterization of Atherosclerotic Plaque. Arterioscler Thromb Vasc Biol. 2002; 22: 1065–1074. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12117718 DOI: https://doi.org/10.1161/01.ATV.0000019735.54479.2F
Makowski MR, Wiethoff AJ, Blume U, Cuello F, Warley A, et al. Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent. Nat Med. 2011; 17: 383–388. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21336283 DOI: https://doi.org/10.1038/nm.2310
Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 1990; 82(3 Suppl): II47-1159. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2203564
La Corte ALC, Philippou H, Ariëns RAS. Role of Fibrin Structure in Thrombosis and Vascular Disease. Adv Protein Chem Struct Biol. 2011; 83: 75–127. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21570666 DOI: https://doi.org/10.1016/B978-0-12-381262-9.00003-3
Tavora F, Cresswell N, Li L, Ripple M, Burke A. Immunolocalisation of fibrin in coronary atherosclerosis: implications for necrotic core development. Pathology (Phila). 2010; 42: 15‑22. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20025475 DOI: https://doi.org/10.3109/00313020903434348
Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, et al. in vivo Molecular Imaging of Acute and Subacute Thrombosis Using a Fibrin-Binding Magnetic Resonance Imaging Contrast Agent. Circulation. 2004; 109: 2023–2029. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15066940 DOI: https://doi.org/10.1161/01.CIR.0000127034.50006.C0
Makowski MR, Forbes SC, Blume U, Warley A, Jansen CHP, et al. in vivo assessment of intraplaque and endothelial fibrin in ApoE−/− mice by molecular MRI. Atherosclerosis. 2012; 222: 43–49. DOI: https://doi.org/10.1016/j.atherosclerosis.2012.01.008
Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, et al. Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques. Circulation. 2001; 104: 1280–1285. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11551880 DOI: https://doi.org/10.1161/hc3601.094303
Sirol M, Aguinaldo JGS, Graham PB, Weisskoff R, Lauffer R, et al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis. 2005; 182: 79–85. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16115477 DOI: https://doi.org/10.1016/j.atherosclerosis.2005.02.013
Jackson RL, Busch SJ, Cardin AD. Glycosaminoglucans : molecular properties, protein interactions, and role in physiological processes. Physiol Rev. 1991; 71: 481–539. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2006221 DOI: https://doi.org/10.1152/physrev.1991.71.2.481
Salisbury BG, Wagner WD. Isolation and preliminary characterization of proteoglycans dissociatively extracted from human aorta. J Biol Chem. 1981; 256: 8050–8057. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7263639 DOI: https://doi.org/10.1016/S0021-9258(18)43386-8
Berenson GS, Radhakrishnamurthy B, Srinivasan SR, Vijayagopal P, Dalferes ER. Proteoglycans and Potential Mechanisms Related to Atherosclerosisa. Ann N Y Acad Sci. 1985; 454: 69–78. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3865616 DOI: https://doi.org/10.1111/j.1749-6632.1985.tb11845.x
Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006; 20: 9–22. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16394262 DOI: https://doi.org/10.1096/fj.05-4682rev
Lindahl U, Hook M. Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem. 1978; 47: 385–417. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/354500 DOI: https://doi.org/10.1146/annurev.bi.47.070178.002125
Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001; 11: 75–82. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11166215 DOI: https://doi.org/10.1016/S0962-8924(00)01897-3
Nugent MA. Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci. 2000; 97: 10301–10303. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10984527 DOI: https://doi.org/10.1073/pnas.97.19.10301
Evanko SP, Raines EW, Ross R, Gold LI, Wight TN. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol. 1998; 152: 533–546. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857967/
Stevens RL, Colombo M, Gonzales JJ, Hollander W, Schmid K. The glycosaminoglycans of the human artery and their changes in atherosclerosis. J Clin Invest. 1976; 58: 470–481. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC333202/ DOI: https://doi.org/10.1172/JCI108491
Ballinger ML, Nigro J, Frontanilla KV, Dart AM, Little PJ. Regulation of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci CMLS. 2004; 61: 1296–1306. pubMed: https://www.ncbi.nlm.nih.gov/pubmed/15170508 DOI: https://doi.org/10.1007/s00018-004-3389-4
Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, et al. Differential Accumulation of Proteoglycans and Hyaluronan in Culprit Lesions: Insights Into Plaque Erosion. Arterioscler Thromb Vasc Biol. 2002; 22: 1642–1648. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12377743 DOI: https://doi.org/10.1161/01.ATV.0000034021.92658.4C
O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, et al. Comparison of Apolipoprotein and Proteoglycan Deposits in Human Coronary Atherosclerotic Plaques: Colocalization of Biglycan With Apolipoproteins. Circulation. 1998; 98: 519–527. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9714108 DOI: https://doi.org/10.1161/01.CIR.98.6.519
Merrilees MJ, Beaumont B, Scott LJ. Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: correlation to patency. Coron Artery Dis. 2001; 12:7–16. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11211169 DOI: https://doi.org/10.1097/00019501-200102000-00002
Radhakrishnamurthy B, Srinivasan SR, Vijayagopal P, Berenson GS. Arterial wall proteoglycans‑biological properties related to pathogenesis of atherosclerosis. Eur Heart J. 1990; 11: 148‑157. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2226523 DOI: https://doi.org/10.1093/eurheartj/11.suppl_E.148
Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, oude Egbrink MGA. The endothelial glycocalyx: composition, functions, and visualization. Pflüg Arch - Eur J Physiol. 2007; 454: 345–59. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17256154 DOI: https://doi.org/10.1007/s00424-007-0212-8
Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med. 2016; 280:97–113. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26749537 DOI: https://doi.org/10.1111/joim.12465
Selleck SB. Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet. 2000; 16: 206–212. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10782114 DOI: https://doi.org/10.1016/S0168-9525(00)01997-1
Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays. 1998; 20: 156–167. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9631661 DOI: https://doi.org/10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R
Wight TN. The extracellular matrix and atherosclerosis. Curr Opin Lipidol. 1995; 6: 326. DOI: https://doi.org/10.1097/00041433-199510000-00013
Scott JE. Structure and function in extracellular matrices depend on interactions between anionic glycosaminoglycans. Elsevier; 2001; 49: 284-289. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11428163 DOI: https://doi.org/10.1016/S0369-8114(01)00152-3
Srinivasan SR, Xu J-H, Vijayagopal P, Radhakrishnamurthy B, Berenson GS. Low-density lipoprotein binding affinity of arterial chondroitin sulfate proteoglycan modulates cholesteryl ester accumulation in macrophages. Atherosclerosis. 1994; 109: 97. DOI: https://doi.org/10.1016/0021-9150(94)93401-0
Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular Consequences of the Association of ApoB Lipoproteins With Proteoglycans. Arterioscler Thromb Vasc Biol. 1997; 17: 1011–1017. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9194748 DOI: https://doi.org/10.1161/01.ATV.17.6.1011
Camejo G, Olofsson SO, Lopez F, Carlsson P, Bondjers G. Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arterioscler Thromb Vasc Biol. 1988; 8: 368–377. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3395272 DOI: https://doi.org/10.1161/01.ATV.8.4.368
Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002; 417: 750–754. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12066187 DOI: https://doi.org/10.1038/nature00804
Borén J, Olin K, Lee I, Chait A, Wight TN, et al. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998; 101: 2658–2664. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9637699 DOI: https://doi.org/10.1172/JCI2265
Imberty A, Lortat-Jacob H, Pérez S. Structural view of glycosaminoglycan–protein interactions. Carbohydr Res. 2007; 342: 430–439. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17229412 DOI: https://doi.org/10.1016/j.carres.2006.12.019
Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res. 1980; 19: 129–137. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7444850 DOI: https://doi.org/10.1016/0049-3848(80)90412-0
Stuckey JA, Charles RSt, Edwards BFP. A model of the platelet factor 4 complex with heparin. Proteins Struct Funct Bioinforma. 1992 ; 14: 277–287. DOI: https://doi.org/10.1002/prot.340140213
Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet Factor 4 Modulates Fibroblast Growth Factor 2 (FGF-2) Activity and Inhibits FGF-2 Dimerization. Blood. 1998; 91: 3289–3299. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9558385 DOI: https://doi.org/10.1182/blood.V91.9.3289.3289_3289_3299
Petersen F, Brandt E, Lindahl U, Spillmann D. Characterization of a Neutrophil Cell Surface Glycosaminoglycan That Mediates Binding of Platelet Factor 4. J Biol Chem. 1999; 274: 12376–12382. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10212210 DOI: https://doi.org/10.1074/jbc.274.18.12376
Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci. 1997; 94: 14683–14688. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9405673 DOI: https://doi.org/10.1073/pnas.94.26.14683
Li W, Johnson DJD, Esmon CT, Huntington JA. Structure of the antithrombin–thrombin–heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol. 2004; 11: 857–862. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15311269 DOI: https://doi.org/10.1038/nsmb811
Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci. 2003; 100:2357–2362. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12604799 DOI: https://doi.org/10.1073/pnas.0437842100
Guerrini M, Agulles T, Bisio A, Hricovini M, Lay L, et al. Minimal Heparin/Heparan Sulfate Sequences for Binding to Fibroblast Growth Factor-1. Biochem Biophys Res Commun. 2002; 292: 222–230. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11890696 DOI: https://doi.org/10.1006/bbrc.2002.6634
Capila I, Linhardt RJ. Heparin–Protein Interactions. Angew Chem Int Ed. 2002; 41: 390–412. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12491369 DOI: https://doi.org/10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B
Desai UR, Petitou M, Björk I, Olson ST. Mechanism of Heparin Activation of Antithrombin Role of Individual Residues of the Pentasaccharide Activating Sequence in the Recognition of Native and Activated States of Antithrombin. J Biol Chem. 1998; 273: 7478–87. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9516447 DOI: https://doi.org/10.1074/jbc.273.13.7478
Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem. 1990; 265: 18263–18271. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2211700 DOI: https://doi.org/10.1016/S0021-9258(17)44747-8
Liaw PCY, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI. Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin. J Biol Chem. 2001; 276: 20959–20965. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11294849 DOI: https://doi.org/10.1074/jbc.M010584200
Uca YO, Hallmann D, Hesse B, Seim C, Stolzenburg N, Pietsch H, et al. Microdistribution of Magnetic Resonance Imaging Contrast Agents in Atherosclerotic Plaques Determined by LA-ICP-MS and SR‑µXRF Imaging. Invest Radiol. 2020 Mar 24 (Manuscript submitted for publication) DOI: https://doi.org/10.1007/s11307-020-01563-z
Collingwood JF, Adams F. Chemical imaging analysis of the brain with X-ray methods. Spectrochim Acta Part B At Spectrosc. 2017; 130: 101–18. DOI: https://doi.org/10.1016/j.sab.2017.02.013
Hare D, Austin C, Doble P. Quantification strategies for elemental imaging of biological samples using laser ablation-inductively coupled plasma- mass spectrometry. Analyst. 2012; 137: 1527–1537. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22314636 DOI: https://doi.org/10.1039/c2an15792f
Kubaski F, Osago H, Mason RW, Yamaguchi S, Kobayashi H, et al. Glycosaminoglycans detection methods: Applications of mass spectrometry. Mol Genet Metab. 2017; 120: 67–77. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27746032 DOI: https://doi.org/10.1016/j.ymgme.2016.09.005
Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006; 35: 512-523. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16729145 DOI: https://doi.org/10.1039/b510982p
Ziegler A, Seelig J. Binding and Clustering of Glycosaminoglycans: A Common Property of Mono- and Multivalent Cell-Penetrating Compounds. Biophys J. 2008; 94: 2142–2149. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18065465 DOI: https://doi.org/10.1529/biophysj.107.113472
Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006; 6: 633–643. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16917509 DOI: https://doi.org/10.1038/nri1918
Li Q, Park PW, Wilson CL, Parks WC. Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury. Cell. 2002; 111: 635–646. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12464176 DOI: https://doi.org/10.1016/S0092-8674(02)01079-6
Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999; 68: 729–777. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10872465 DOI: https://doi.org/10.1146/annurev.biochem.68.1.729
Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of Protein Function by Glycosaminoglycans—as Exemplified by Chemokines. Annu Rev Biochem. 2005; 74: 385–410. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15952892 DOI: https://doi.org/10.1146/annurev.biochem.72.121801.161747
Fischer JW, Steitz SA, Johnson PY, Burke A, Kolodgie F, et al. Decorin Promotes Aortic Smooth Muscle Cell Calcification and Colocalizes to Calcified Regions in Human Atherosclerotic Lesions. Arterioscler Thromb Vasc Biol. 2004; 24: 2391–2396. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15472131 DOI: https://doi.org/10.1161/01.ATV.0000147029.63303.28
McDonald JA. Extracellular matrix assembly. Annu Rev Cell Biol. 1988;4(1):183–207. DOI: https://doi.org/10.1146/annurev.cb.04.110188.001151
Costa DS da, Reis RL, Pashkuleva I. Sulfation of Glycosaminoglycans and Its Implications in Human Health and Disorders. Annu Rev Biomed Eng. 2017; 19: 1–26. PubMed: https://www.ncbi.nlm.Fnih.gov/pubmed/28226217 DOI: https://doi.org/10.1146/annurev-bioeng-071516-044610
Thacker BE, Xu D, Lawrence R, Esko JD. Heparan sulfate 3-O-sulfation: A rare modification in search of a function. Matrix Biol. 2014; 35: 60–72. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24361527 DOI: https://doi.org/10.1016/j.matbio.2013.12.001
Busby TF, Argraves WS, Brew SA, Pechik I, Gilliland GL, et al. Heparin Binding by Fibronectin Module III-13 Involves Six Discontinuous Basic Residues Brought Together to Form a Cationic Cradle. J Biol Chem. 1995; 270: 18558–18562. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7629186 DOI: https://doi.org/10.1074/jbc.270.31.18558